Widespread acceptance of liquid biopsy technique in North America and steady adoption in developing regions is expected to drive global liquid biopsy market revenues. The global market is expected to reach US$ 407 Mn in 2016, up from US$ 351 Mn in 2015. North America will continue to remain the largest market for liquid biopsy, accounting for over 50% share of the global market.
The minimally-invasive nature and economical affordability of liquid biopsy tests will play a key role in bolstering demand globally. FDA approvals for non-invasive diagnostic tests for cancers is expected to have a positive influence on the growth of the market.
Request a Sample Report: http://www.futuremarketinsights.com/reports/sample/rep-gb-1396
An increasing number of biotechnology and pharmaceutical companies are pushing the demand for liquid biopsy for anti-cancerous drug development. Moreover, oncologists are more inclined toward liquid biopsy for cancer detection. Government funding for R&D and clinical trials for diagnostics, treatment, and prevention are other key factors fuelling adoption of liquid biopsy. In contrast, higher cost of liquid biopsy compared to conventional diagnostic techniques, and low awareness regarding liquid biopsy tests can pose challenges to growth.
By bio marker type, circulating tumour cells (CTCs) segment is expected to form the most attractive market segment, contributing more than 60% of the revenue share to the market. On the basis of the sample type, the segment for blood sample will reflect the highest growth potential, with over 93% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth throughout 2016.
By disease indication, lung cancer segment is expected to dominate the market, in terms of revenues. By end user, cancer institutes are estimated to represent a revenue share of around 38% — significantly higher compared to other end-use segments, such as hospitals, academic institutes, and diagnostic centres.
Some of the key players in the global liquid biopsy market include Genomic Health, Inc., Biocept, Qiagen, Inc., Trovagene, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation. A majority of key companies are concentrating on mergers, acquisitions, and partnerships; while most of them are prioritising innovative diagnostics and technological upgrades for better penetration in developing regional markets.
Long term outlook: The global liquid biopsy market is projected to expand at a CAGR of 21.7% by 2026 end, reaching a value of US$ 2.89 Bn.
Free Analysis on Global Liquid Biopsy Market Revenue by Region: http://www.futuremarketinsights.com/reports/liquid-biopsy-market
Table Of Content
- Executive Summary
- Assumptions and Acronyms
- Research Methodology
- Liquid Biopsy Market Overview
4.1.1. Liquid Biopsy Market Definition
4.1.2. Liquid Biopsy Market Taxonomy
4.2. Liquid Biopsy Market Dynamics
4.3. Regional Cancer Epidemiology
4.4. Reimbursement Scenario
4.5. Pipeline Assessment, By Products
4.6. Product Penetration and Pricing Impact
4.7. Revenue Potential Liquid Biopsy
4.8. Case Studies
- Global Liquid Biopsy Market Forecast
5.1. Market Value (US$ Mn) Forecast
5.1.1. Y-o-Y Growth Projections
5.1.2. Absolute $ Opportunity
5.2. Liquid Biopsy Market Trends
5.3. Global Liquid Biopsy Market Snapshot (2015)
5.3.1. Market Share, By Sample Type
5.3.2. Market Share, By Disease Indication
5.3.3. Market Share, By Marker Type
5.3.4. Market Share, By End User
Download Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-1396
More From FMI’s Cutting-edge Intelligence:
- High Content Screening (HCS) Market:
- Automated CPR Devices Market
- Automated Breast Ultrasound System Market
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: email@example.com
For Media Enquiries: firstname.lastname@example.org
Research Report: https://www.futuremarketinsights.com/reports/liquid-biopsy-market
Press Release Source: https://www.futuremarketinsights.com/press-release/liquid-biopsy-market